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PRECLINICAL DEVELOPMENT 
P rograr'" (Fujisawa Pharmaceutical, Japan) (generic: tacrolimus), also known 
as FKS06 in clinical trials and as FK900S06 in preclinical trials, is the first 
baseline immunosuppressive agent approved by the Food and Drug Adminis-
tration in over 10 years. In 1982, Fujisawa Pharmaceutical Company insti-
tuted a drug screening program' to search for new immunosuppressive agents. 
In May 1984, Goto and Kino described the in vitro immunosuppressive qualities 
of a fermentation extract of strain 993 of Streptomyces (Streptomyces tsukubaensis}.1.3 
As reported by Ochiai in August, 1986 at the 11 th International Congress of 
the Transplantation Society (Helsinki, Finland), FK900506 was described as a 
new macrolide antibiotic with potent in vivo immunosuppressive activity.4 Further 
preclinical data on FK900S06 was presented the following year 0 une, 1987) 
at the European Society of Organ Transplantation in Sweden. 5 
The molecular structure of FKS06 is untelated to cyclosporine, and the 
two drugs have different cytosolic binding sites.6 Although both drugs inhibit 
T-Iymphocyte activation and subsequent cytokine production, there is a prac-
tical difference in the clinical utility of the two agents. Murase et al demon-
strated the ability of FKS06 to be used to reverse ongoing, established rejec-
tion.7 The ability of FKS06 to be used to reverse ongoing, established rejection, 
is not a characteristic of cyclosporine. It was this property that was utilized in 
the first clinical trials of FKS06. 8.9 
CLINICAL TRIALS 
The first clinical trial of FKS06 began at the University of Pittsburgh in 
February of 1989, under an "Investigational New Drug" (lND) application 
maintained at the University of Pittsburgh. This followed lengthy discussions 
between the principal investigators, the Food and Drug Administration and 
the University of Pittsburgh Institutional Review Board (IRB). Dosing guide-
lines were developed by careful extrapolation of doses in animal models, nor-
malizing dose to body surface area. A special committee of the IRB was formed 
to review protocols and results of those protocols. 
Later trials for liver, kidney and intestinal transplantation were also initi-
ated under separate IND applications sponsored by Fujisawa. A primary kid-
ney transplant trial was started in Japan in 1990, and a multicenter primary 
liver transplant trial was started in both Europe and the United States in 1990. 
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The initial doses of FK506 recommended for the early 
trials were the same as those in the initial University 
of Pittsburgh trials, although the suggestion of dose 
reduction by the Pittsburgh investigators were not 
incorporated until midway through the pivotal 
multicenter European and American trials. Subse-
quently, dose finding studies have been completed 
for both primary liver and kidney transplant, verify-
ing the need for lower maintenance oral FK506 doses 
(Fujisawa, personal communications). 
LIVER TRANSPlANTATION 
The first clinical use of FK506 was for the indi-
cation of uncontrolled liver allograft rejection and were 
therefore considered treatment failures of conventional 
immunosuppression. The results of this experience 
revealed a marked ability to reverse ongoing rejec-
tion, even in cases where chronic changes were ob-
served.8•9-12 Between 50% and 70% of patients treated 
by conversion to FK506 had both clinical and 
histopathologic improvement. In a recent long term 
followup of 113 patients with chronic rejection, 75% 
of patients were still alive at 3 years following FK506 
conversion, and 65% of liver allografts were still func-
tioning (Fig. 10.4.0.12 The United States Multicenter 
FK506 Liver Study Group has recently reported their 
analysis of the prognostic factors for successful con-
version from cyclosporine to FK506 based immuno-
suppressive therapy for refractory liver rejection. 13 At 
one month after conversion, 54% of patients were 
noted to have complete or partial improvement. By 
6 months after conversion, this benefit was noted in 
67% of patients, and 86% at one year. In this series 
in which the most refractory rejections were converted 
from cyclosporine to FK506, the one year actuarial 
graft and patient survival after conversion was 50% 
and 72%, respectively. 
The ability of FK506 to reverse ongoing rejec-
tion was the impetus to begin trials of FK506 as initial 
baseline immunosuppression following primary liver 
transplantation. Three randomized trials have been 
performed, comparing FK506 with cyclosporine in 
primary liver transplantation. While each trial had 
unique features regarding the immunosuppressive regi-
mens and the characteristics of the patient groups, 
one of the common primary endpoints was the fail-
ure of the defined immunosuppressive treatment to 
prevent and control rejection. In the University of 
Pittsburgh series, low risk candidates were random-
ized to FK506 with steroids as compared to cyclo-
sporine with steroids. 14 One hundred fifty-four pa-
tients were enrolled between February 17, 1990 and 
December 30, 1991. The 1 year patient and graft 
survival, as analyzed by intent to creat, was 92% and 
88% respectively for FK506, compared to 85% and 
79% respectively for cyclosporine. The followup at 
2 years revealed that the modest increase in patient 
and graft survival in the FK506 limb was retained. 
The good results in the cyclosporine limb was due, 
in part, to the ability of FK506 to treat rejection in 
the cyclosporine group. The freedom from rejection 
was statistically greater in the FK506 treated group, 
Fig. 10.4. 1. Kaplan-Meier estimates 
of patient and graft survival of liver 
Jllograft in patients on cyciosporine 
who have been converted to FK506 
for biopsy documented chronic re-
jection. Reprinted with permission 
of A. Jain. 
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as compared to the cyclosporine treated group. In 
addition, the freedom from steroid use, and the lower 
incidence of hypertension, were prominent features 
of patients treated with FK506. 
The results in this single center study have been 
compared to two other randomized liver transplant 
trials conducted in the United States and in Europe 
(preliminary data presented at the International Liver 
Transplantation Society, Toronto, Canada, October, 
1993 and at the Food and Drug Administration, 
December 1993). In each series, over 500 patients 
were entered into the combined limbs. Using a regi-
mented FK506 treatment arm, the results obtained 
in these trials support the findings at the University 
of Pittsburgh. The European study demonstrated an 
enhanced patient and graft survival in the FKS06 limb, 
when compared to the CsA limb. Although the pa-
tient survival was similar in both groups in the Ameri-
can study, there was a slight benefit in graft survival 
in the FKS06 limb. In both series, approximately 10% 
of cyclosporine- treated patients required FKS06 con-
version to treat refractory rejection. This minimized 
the differences between survival in the FK506 and 
cyclosporine-treated groups. In both studies, there was 
less rejection in the FKS06 limb, and the overall dosing 
of steroids was less in the FKS06 limb. Lake et al15 
reported that FKS06 based immunosuppression was 
found to lead to significantly lower overall hospital 
charges associated with liver transplantation, prima-
rily due to less rejection, and the coSts associated with 
treating rejection. 
Todo et al described the impact of FK506 in liver 
transplantation at a single center with a large cohort 
of patients treated with FK506 as primary immuno-
suppression. 16 In spice of increasing medical severity 
.. _-_ .. _ .. __ ._ .. _--_. .-..•..•. - .. ----
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and use of expanded donor pool liver allografts, the 
one year patient and graft survival over the past 13 
years has shown a progressive improvement (see 
Table 10.4.1). In the FKS06 era (beginning mid-1989), 
the 1 year patient (83%) and graft (72%) survival 
represent a significant improvement over the results 
obtained in the immediately preceding era of 
cyclosporine immunosuppression. 
KIDNEY TRANSPIANTATION 
The application of FK506 rescue therapy to kid-
ney transplantation was an extension of the experience 
gained in liver transplantation. The notable differ-
ence between the two organ systems is the predomi-
nance of arteriopathy and sclerosis of epithelial struc-
tures in the kidney allografts undergoing chronic 
rejection. This was found to limit the ability of FK506 
to rescue kidney allografts with this pathologic find-
ing. In a series of 35 patients, those with ongoing 
acute cellular rejection had a successful conversion 
rate of 71 %, while those with stigmata of chronic 
rejection were not able to be rescued. 17 Those with 
living related kidney transplants had a higher rate of 
rescue (73%) as compared to those with cadaveric 
grafts (50%), probably related to an earlier referral 
for FK506 rescue therapy. 
A randomized trial, utilizing FK506 in a double 
drug regimen (FK506 and steroids) versus a triple 
drug regimen (FK506, steroids and azathioprine), was 
performed in kidney transplantation at the U niver-
sity of Pittsburgh. IS Two hundred four patients were 
entolled; there were no specific exclusion criteria based 
on immunologic or transplant history. Thirty per-
cent of the patients were undergoing a retransplanr. 
with 17% of the recipients being sensitized 
Table 10.4.1. Orthotopic liver transplantation-O 1/01/8 I to 12/31/93 
Year of Number of Patient Graft 
Transplantation Patients Survival Survival 
One Year Five Years One Year Five Years 
1981 26 65% 54% 57% 43% 
1982 62 50% 44% 35% 29% 
1983 75 68% 56% 52% 41% 
1984 132 77% 70% 61% 50% 
1985 178 67% 57% 51% 41% 
1986 264 72% 59% 57% 44% 
1987 295 75% 66% 59% 51% 
1988 399 76% 65% 64% 51% 
1989 395 80% 65% 65% 52% 
1990 442 84% 71% 
1991 368 81% 70% 
1992 289 83% .... ...,0/ I ... /u 
1993 304 83% 73% 
Total 3229 78% 66% b4% 52% 
""ote: The survival rates were computed using the Kaplan-Meier method_ 
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(PRA > 40%). The 1 year actuarial patient and graft 
survival for the two drug versus three drug regimen 
were: 9S% and 90% versus 91 % and 82%, respec-
tively. No differences were noted in the kidney func-
tion with the mean serum creatinine of 1.8 ± 0.8 mgt 
dt. The rejection rate in the three drug regimen was 
less than that for the two drug regimen (37% vs 51%), 
although this was not statistically significant (p = 0.07). 
Crossover from one group to another was not un-
common; 2S% of the two drug group were given 
azathioprine, principally due to rejection, while 4S% 
of the three drug group required discontinuation of 
azathioprine because of leucopenia or hepatic dys-
function. 
At the University of Pittsburgh, the impact of 
FKS06 in kidney transplantation is shown in Table 
10.4.2. Since mid-1990, the routine use of FKS06 
for kidney transplantation has improved the one year 
graft survival to 86%, which represents a significant 
improvement in graft survival as compared to the 
immediately preceding era of cydosporine immuno-
suppression. 
HEART TRANSPLANTATION 
Armitage and co-workers at the University of 
Pittsburgh have reported their experience with FKS06-
based immunosuppression following heart transplan-
tation. 19.20 In 8 patients, FK506 was utilized as res-
cue therapy for patients suffering from persistent, 
refractory cardiac rejection on cydosporine, azathio-
prine and steroids. All of these 8 patients had re-
ceived and failed one or more courses of antilym-
phocyte therapy while on cydosporine therapy. In 
keeping with the previous experiences with rescue 
therapy, all of these patients had demonstrated im-
provement in the histopathology after FKS06 con-
verSIon. 
Seventy-two adult patients were given FKS06 as 
primary immunosuppression following heart transplan-
tation. 20 The one year patient and graft survival was 
92%. The freedom from rejection at 90 days was 41 % 
and at 180 days was 34%. Renal dysfunction was 
frequently noted, and the mean serum creatinine at 
6 months following transplantation was 2.2 mg!dl. 
The incidence of diastolic hypertension was S4%, but 
was considered mild, as treatment consisted of a single 
agent in all cases. The incidence of new onset diabe-
tes was 20% in this group of patients. 
LUNG TRANSPLANTATION 
A small experience of pediatric lung transplanta-
tion under FKS06 has been reported by Armitage and 
co-workers.21 Eleven patients received FKS06, two of 
whom have died because of early infectious compli-
cations. While rejection episodes were no different 
between FK506 and cyclosporine, unlike the cydo-
sporine experience, antilymphocyte preparations have 
not been required to reverse rejections on FKS06. 
In addition, hypertension was not seen in the FKS06 
group, as compared to an incidence of SO% in the 
cyclosporine group. 
A prospective randomized trial of primary adult 
pulmonary transplantation was conducted at the U ni-
versity of Pittsburgh. 22 Azathioprine was combined 
with either FKS06 or cydosporine, resorting to us-
ing steroids only if the recipient encountered more 
than one episode of rejection. Twenty eight patients 
were randomized to FKS06, 29 patients were ran-
Table 10.4.2. Kidney transplantation-O 1/0 l/B 1 to 12/31/93 
Year of Number of Patient Graft 
Transplantation Grafts Survival Survival 
One Year Five Years One Year Five Years 
1981 103 96% 86% 71% 47°/., 
1982 119 87% 82% 73% 55% 
1983 160 97% 91% 73% 56% 
1984 204 90% 79% 68% 49% 
1985 175 94% 86% 76% 54% 
1986 264 90% 78% 69% 50% 
1987 188 95% 85% 73% 55% 
1988 209 95% 86% 78% 59% 
1989 226 92% 83% 76% 55% 
1990 203 93% 78% 
1991 160 95% 84% 
1992 201 93% 87% 
1993 189 98% 90% 
Total 2401 93% 84'10 77°;<) 57% 
,"ote: The survival rates w('re computed using the Kaplan·Meler method. 
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domized to cyclosporine. The 6 month graft survival 
was statistically better in the FK506 group as com-
pared to the cyclosporine group (86% vs 69% re-
spectively, p < 0.05). Twenty-one percent of the FK506 
patients were rejection free at 6 months, as compared 
to only 3% of the cyclosporine patients. At one year 
after lung transplantation, the rate of obliterative 
bronchiolitis, the manifestation of chronic rejection 
in lung allografts, was statistically less in the FK506 
group as compared to the cyclosporine group 
(Dr. Robert Keenan, personal communication). 
INTESTINAL TRANSPLANTATION 
One way to assess the impact of a new immuno-
suppressive agent in transplantation is the ability to 
successfully transplant organs which were not con-
sidered feasible with standard immunosuppression. Suc-
cess with intestinal transplantation under cyclosporine 
immunosuppression has been sporadic. The use of 
FK506 for intestinal transplantation has allowed for 
better control of rejection, with resultant significant 
improvement in patient and graft survival. 23-25 
Forty-three patients were transplanted between 
May 2. 1990 and April 15. 1993. A total of 45 grafts 
were transplanted into the 43 recipients. Fifteen of 
these patients received an isolated intestinal graft. 21 
received both a liver and intestine and 7 received a 
multivisceral graft. Two retransplantations were per-
formed. one as an isolated intestinal graft. and the 
other a combined liver/intestine. 
There were 22 children and 21 adults, with a 
preponderance of children requiring liver/intestine 
transplantation and adults receiving intestinal trans-
plants alone. The sex distribution was similar between 
the three different types of intestinal transplants. 
The mean age for the pediatric population was 
3.5 ± 3.7 years of age. and for the adults. 33.3 ± 10.2 
years of age. 
Short gut syndrome due to Crohn's disease was 
the most common reason for isolated intestinal trans-
plantation. while neonatal intestinal complications with 
resulting TPN-induced liver failure was the most 
common reason for combined liver and intestinal 
transplantation. Mesenteric vascular occlusion. includ-
ing complications due to inherent hypercoagulopathy. 
was the most common reason for multivisceral trans-
plantation. 
The mean followup of the 30 survivors follow-
ing intestinal transplantation was 17 ± 9 months (range 
6-39 months). The Kaplan-Meier estimates of actu-
arial survival for the 43 patients revealed an overall 
3. 6. 12. and 24 month patient survival of 88%. 84%. 
81 % and 74%. respectively. When analyzed by co-
horts corresponding to intestine alone. liver/intestine 
and multivisceral. the one vear survival was 93%. 71 % 
,md 86%, respectively. The corresponding two year 
actuarial survival was 83%, 65% and 86%. Thirteen 
187 
patients in all groups died. Four deaths occurred in 
the isolated small bowel transplant group, eight in 
the combined liver/intestine group and one in the 
multivisceral group. Generally the causes of death could 
be categorized into technical complications (3), op-
portunistic infections (2), posttransplant lympho-
proliferative disease (2), persistent rejection (2). sepsis 
following graft removal (2) and others (2). In one 
intestine transplant recipient. death was due to a cath-
eter-related pulmonary embolism which occurred 8 
months following allograft enterectomy. 
Graft survival was determined for 45 grafts. which 
included 43 primary and 2 retransplants. The esti-
mated actuarial survival of all grafts was 80%, 78%. 
72% and 59% at 3. 6, 12 and 24 months, respec-
tively. Because of the ability to maintain recipients 
of small bowel allografts on TPN. following removal 
of the transplanted graft. the discrepancy between the 
patient and graft survival was greater in this group. 
as compared to the combined liverlintestine and 
multivisceral groups. Sixteen of the 45 implanted grafts 
were lost. either due to patient death lO or following 
enterectomy.6 The indication for allograft enterectomy 
was refractory rejection in all 6 patients_ 
DOSING OF FK506 
Specific guidelines for the use of FK506 baseline 
immunosuppression will depend on the organ trans-
planted. Generally, orally administered FK506 is pre-
ferred over the intravenous route. However. when 
absorption of oral FKS06 is not reliable. intravenous 
administration may be mandatory. 
At the University of Pittsburgh. initiation of 
FKS06 therapy is either intravenously as a constant 
24 hour infusion. between doses of 0.05-0.15 mg/ 
kg/d. or orally at 0.3 mg/kg/d (in two divided doses). 
Following liver transplants. lower initiating doses are 
given, while for kidney and heart transplants. inter-
mediate doses are employed, and the highest levels 
are used for intestine and lung transplants. Abu-Elmagd 
et al have previously shown that hepatic dysfunction 
significantly impacts on FK506 metabolism, and that 
lower doses of FKS06 are needed to achieve similar 
FK506 plasma concentrations. when compared to good 
hepatic function. l6 Overlap of intravenous and oral 
administration is not the general rule, except with 
intestinal transplantation. in which a tranSition pe-
riod of approximately 3-5 days is used. 
At the University of Pittsburgh. FK506 levels are 
determined by plasma concentrations using an ELISA 
assay. as previously reported (see below). While on 
constant intravenous dosing of FK506. levels between 
2-4 nglml are used to help determine dosing guide-
lines. Trough levels are determined immediately prior 
(0 administration of oral FK506. and levels of 1-2 
nglml are used to help guide chronic FK506 admin-
istration. Dose reductions of FK506 are made if the 
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liver function was compromised (see above), or if there 
are complications of nephrotoxicity or neurotoxicity. 
Dose increases of FK506 are made if rejection is de-
tected by biopsy. The dose adjustability of FK506 
allows the physician to titrate the immunosuppres-
sive baseline to the threshold of rejection, rather than 
to arbitrarily rely on target drug levels, which may 
represent overimmunosuppression for some, and 
underimmunosuppression for others. 
Corticosteroids are also individualized for each 
organ system. Generally, methylprednisolone is given 
as a single bolus of 1 g following reperfusion, and then 
as a steroid taper for 5 days, beginning at 200 mg/d 
and ending at 20 mg/d of methylprednisolone. A 
maintenance dose of 20 mg/d of prednisone or me-
thylprednisolone is given and tapered slowly, as tol-
erated. In lung transplantation, the steroid taper is 
omitted in the early posttransplant period, because 
of concerns about bronchial healing. 
Mild to moderate acute rejection is generally 
treated with a single bolus of methylprednisolone fol-
lowed by a 5 day recycle of methylprednisolone starting 
at 200 mg/d and ending at 20 mg/d. In heart trans-
plant recipients. grade III or IV rejections (modified 
Billingham criteria) are usually given three consecu-
tive Ig boluses of methylprednisolone. We have found 
that augmented steroid dosing has been required in 
approximately 50% of patients, who have not respond 
to increasing doses of FK506. Azathioprine can be 
added at doses of 0.5-1.0 mg/kg/d if there is persis-
tent rejection. and when the white blood cell count 
is maintained above 3.500/mm3• OKT3 (ORTHO. 
Raritan. NJ) is given at 5-10 cc/d over a 7-10 day 
course for severe rejection. In our experience. OKT3 
was required in approximately 15-20% of transplant 
recipients. 
MONITORING FKS06 
The results of clinical studies suggest that FK506 
is effective for solid organ transplantation. but that 
toxicity is associated with high plasma or whole blood 
levels of FK506.27 Thus the dosing schedule and moni-
toring techniques for FK506 continue to be modi-
fied. at different centers. with different organs. One 
of the principle issues regarding the use of FK506 
has been with monitoring of drug levels. In Europe 
and at other centers in the United States. whole blood 
levels have been utilized. This measures not only 
plasma levels. but also cell bound FK506. The prin-
(:iple advantage of whole blood levels are the higher 
FK506 levels which can be detected. making adjust-
ments in FK506 dosing potentially easier. Recom-
mended therapeutic whole blood levels are between 
10-20 ngl ml with the same ca years regarding dose 
adjustments for rejection or toxicity. In addition. whole 
blood monitoring offers the advan~age of faster analysis 
rimes and less variability of sample storage and prepa-
ration disparity. The principal limitations of whole 
blood monitoring using automated systems (Abbott), 
has been the insensitivity of the assay at the lower 
end of detection « 5 ng/ml). 
The issue of appropriate monitoring either whole 
blood FK506 levels and/or plasma FK506 levels, is 
reminiscent of the disparity in cydosporine monitoring 
techniques.28 
TOXICITY 
FK506 is not without its limitations.27•29 Toxic-
ity profiles for FK506 are similar to that of cyclo-
sporine, perhaps because of similar mechanisms of 
action. Both FK506 and cyclosporine administration 
have been associated with side effects, many of which 
are similar, and some of which are peculiar to a given 
organ transplant. Adverse reactions requiring treat-
ment or adjustment of FK506 doses can be catego-
rized into four primary areas. These are: (1) alter-
ations in kidney function; (2) alterations in glucose 
metabolism; (3) neurotoxicity; and (4) susceptibility 
to infection or malignancy. 
One of the major benefits of FK506 appears to 
be a relative lack of some of the side effects of 
cyclosporine. Some of these are cosmetic, such as 
hirsutism and gingival hyperplasia. which has not been 
seen with FK506. Other more significant side effects. 
such as hypertension. appear to be less in the FK506 
patients than for those on cyclosporine. The ability 
to use less steroids in patients with FK506. when 
compared to cyclosporine. may result in less compli-
cations ascribed to chronic steroid use. In one study 
where FK506 was compared to cyclosporine in pedi-
atric renal transplant recipients. 78% of all FK506 
recipients were off steroids. JO Significant improvement 
in the growth pattern of preadolescents on FK506 
mono therapy was noted. when compared to those on 
FK506 and steroids. or cyclosporine and steroids. 
A clearer profile of adverse reactions and side 
effects of FK506 has been accumulated. In humans. 
rhe principal side effects of FK506. in order of de-
creasing frequency. are: insomnia. tremors. headaches. 
muscle aches. itching. fatigue. visual sensitivity to light 
and GI symptomsK~? In a prospective. randomized 
study. the side effects of FK506 were compared ro 
that of cyclosporine. The only differences between 
the t~o drugs were an increased incidence of head-
aches and insomnia in the FK506 group. while those 
on cyclosporine had an increased incidence of hair 
growth. 14 
The treatment for the four areas of toxicity var-
ies to a large extent to the degree of toxicity. Gener-
ally. toxicity improves with lowering the dos.!s of 
FK506. Some reactions. such as the development of 
"!ysarrhrias. may be idiosyncratic or require multiple 
bctors in order to become apparent. and therefore 
may not respond to decreased doses of FK506. Spe-
Tacrolimus in Solid Organ Transplantation 
cific therapy or supportive measures are indicated until 
the toxicity resolves. The requirement for hemodialysis 
in liver transplant patients is such an example. Re-
nal dysfunction in these cases is generally reversible. 
The effect of FK506 on fertility and on a fetus 
is not fully known. Of the 12 female patients treated 
with FK506 who became pregnant, there were two 
fetal losses, one from CMV infection and the other 
from premature delivery (24 weeks). The 10 other 
babies are healthy and without birth defects.31 
CONCLUSIONS 
While impressive gains in patient and graft sur-
vival have been obtained in solid organ transplanta-
tion. rejection continues to playa significant role in 
morbidity and mortality. A search for new immuno-
suppressive agents must be able to impact on the rates 
and severity of rejection. Ample clinical reports cor-
relate the adverse impact of rejection on long term 
graft survival. In the clinical trials presented here, 
FK506 appears to provide a baseline immunosuppres-
sion which is more potent than cyclosporine. At our 
institution. this is correlated with enhanced patient 
and graft survival at one year and beyond. In addi-
tion, the impact of FK506 on previously "forbidden" 
transplantation, has been dramatic, with the intro-
duction of a successful intestinal transplantation pro-
gram and enhanced results of lung transplantation. 
Given the effectiveness of current polypharmacy 
in minimiz.ing graft loss from rejection, improvement 
in the classical primary endpoint of patient and graft 
survival will be difficult, taking into consideration 
the complexity of factors which impact on this end-
point. Secondary endpoints, such as morbidity and 
quality of life issues, are areas in which newer immu-
nosuppressive agents will have a noticeable impact. 
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